ArticleJournal of cancer research and clinical oncology2026
Longer-term response to SARS-CoV-2 vaccination after allogeneic blood stem cell transplantation.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRecipients of allogeneic haematopoietic stem cell transplantation (alloHSCT) are at increased risk of COVID-19 and lower vaccine immunogenicity. This study assessed vaccine immunogenicity and safety in these patients.
methodsWe analyzed the serological response after the 2nd and 3rd SARS-CoV-2 vaccination as well as potential factors influencing this response. Data were obtained from internal hospital records. In addition, a questionnaire was used to evaluate the vaccination status, vaccination side effects and the course of expired COVID-19 disease.
resultsIn total, 114 patients (median age 62, range 27 - 70) were enrolled between July and September 2022, with 55 females (48.2%). One year later a follow up was conducted. Most patients (89.4%) were vaccinated at least twice, 66.7% received three vaccinations, and 10.5% refused the vaccination. The mRNA vaccines were predominantly used. Most patients responded and reached SARS-CoV-2 spike IgG titers after the 2nd (81.8%) or 3rd (96.1%) vaccination. Patients vaccinated within 24 months of alloHSCT had significantly lower anti-spike IgG levels than those vaccinated later (p=0.017). Common side effects included arm pain (34%), swelling (14%), and limb pain (17%).
conclusionVaccination was feasible and well-tolerated in alloHSCT recipients. Timing of vaccination influenced immune response, with a stronger response after the 3rd dose compared to the initial series.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.